Given findings from the LIFE trial, are there any benefits in using Entresto over valsartan alone in HFrEF patients? 

Thank you for your question.

The LIFE trial studied more advanced heart failure patients. In this patient population, there was no apparent difference in overall outcomes between the two groups in the primary and secondary endpoints but a rise in non-life threatening potassium levels in the Entresto group. Based on this, there is a suggestion that valsartan alone is as effective and may be in fact be better due to not elevating potassium levels as much.

A few observations:

1. the Entresto group had ...

Quite a small clinical trial to fully generalize to all patients who fall in a more advanced ambulatory HF spectrum, if BP tolerates ARNI, I often consider trying it. Invariably given the high risk of this patient population, may not be able to recover them durably on medical therapy and would be considering next treatment option in their future whether it be deviced base therapy or Transplant/VAD.